SBRT Effective in Lung Cancer Patients 80 and Older
This video examines the safety and efficacy of definitive stereotactic body radiation therapy in patients 80 and older with inoperable, early-stage lung cancer.
In this video, Richard Cassidy, MD, of the Winship Cancer Institute at Emory University in Atlanta, discusses results of a multi-center review that looked at the safety and efficacy of definitive stereotactic body radiation therapy (SBRT) in patients age 80 and older with inoperable, early-stage non–small-cell lung cancer.
The researchers identified 58 consecutive patients treated at four locations in the Atlanta area between 2010 and 2015. With a median follow-up of 19.9 months the estimated 2-year cancer-specific survival rate was 73%, with an overall survival rate of 57%. Rates of cancer-specific survival were higher for patients who were not active smokers (hazard ratio [HR], 0.14; P = .03) and were lower both for patients who had previously been diagnosed with lung cancer (HR, 7.75, P = .01) and in older patients (HR, 1.19, P = .04).
Cassidy presented the results (abstract 111) at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
